Home » Osteoporosis Treatments

Osteoporosis Treatment — A Consultant-Led, Anabolic-First Approach

The London Osteoporosis Clinic combines pharmacological treatment, therapeutic exercise, and clinical nutrition in a personalised, consultant-supervised bone health programme.

Effective osteoporosis treatment is not a single intervention — it is a structured, sustained clinical strategy. At the London Osteoporosis Clinic, we approach treatment through what we call an anabolic-first philosophy: wherever clinically appropriate, the goal is not simply to slow bone loss but to stimulate new bone formation, shift the remodelling balance back toward net gain, and achieve measurable improvement in bone mineral density.

For most patients, the most effective pathway combines several complementary elements: the right pharmacological treatment for their clinical profile and risk factors, a progressive therapeutic exercise programme designed to provide osteogenic loading stimulus, and a clinical nutrition strategy addressing the micronutrient requirements of bone formation. None of these three is sufficient alone.

Under consultant supervision at LOC, patients following the BoneRevive® Programme achieve an average 8–12% annual improvement in bone mineral density — a clinically significant change that moves many patients from the osteoporosis into the osteopenia range within two years. The tabs below describe each treatment component in detail.

Pharmacological

Consultant-prescribed treatment matched to your clinical profile, fracture risk, and tolerability.

→ View drug treatments

Therapeutic Exercise

Osteogenic loading programmes designed by clinical exercise specialists for your DXA profile.

→ View exercise classes

Clinical Nutrition

Personalised bone-supportive micronutrition from a registered nutritional therapist.

→ View memberships

Monitoring

Regular DXA reassessment to measure treatment response and adjust the pathway objectively.

→ Book assessment

The BoneRevive® Programme is the London Osteoporosis Clinic’s consultant-led, structured bone health pathway — combining clinical assessment and monitoring, personalised pharmacological treatment where indicated, progressive therapeutic exercise, and clinical nutrition into a single integrated programme with regular outcome measurement.

Initial Consultant Assessment — comprehensive clinical history, fracture risk stratification using FRAX, baseline DXA scan with trabecular bone score, blood panel, and personalised treatment plan.
Medical Treatment (where indicated) — consultant-prescribed pharmacological therapy matched to the patient’s clinical profile, risk factors, co-morbidities, and preferences.
Therapeutic Exercise — a progressive, clinically designed osteogenic loading programme delivered by a specialist Strength & Conditioning Coach, adapted to the patient’s DXA findings and fracture risk.
Clinical Nutrition — personalised calcium, Vitamin D, and micronutrient strategy from a registered nutritional therapist, addressing absorption, deficiency, and anti-inflammatory dietary factors.
Regular Monitoring — DXA follow-up at 12–24 month intervals to measure treatment response objectively. Treatment is adjusted based on results, not assumptions.

Clinical outcome: patients in the BoneRevive® Programme achieve an average 8–12% annual improvement in bone mineral density under consultant supervision — measurable, sustained improvement that significantly reduces long-term fracture risk.

Find out more about the BoneRevive® Programme and Memberships →

Pharmacological treatments for osteoporosis fall into two broad categories. Understanding the distinction is important when discussing treatment options with your consultant:

Antiresorptive Agents: Slow or prevent further bone loss by inhibiting osteoclast activity — the cells that break down bone. They stabilise bone density and reduce fracture risk but do not directly build new bone. (Examples: bisphosphonates, denosumab, raloxifene, HRT)
Anabolic Agents: Stimulate new bone formation by activating osteoblast activity — the cells that build bone. They can achieve meaningful bone density gains and are particularly appropriate for patients with very low bone density or high fracture risk. (Examples: teriparatide, romosozumab, abaloparatide)

Antiresorptive Group

Bisphosphonates

UK brand: Alendronic acid (Binosto, Fosamax); Risedronate (Actonel); Ibandronate (Bonviva); Zoledronic acid (Aclasta)

Mechanism: Inhibit osteoclast-mediated bone resorption, reducing both cortical and trabecular bone loss. First-line pharmacological treatment for most patients with osteoporosis.

Administration: Oral weekly (alendronic acid, risedronate) or monthly (ibandronate); IV annually (zoledronic acid / Aclasta).

Clinical note: IV zoledronic acid is preferred for patients with GI intolerance to oral bisphosphonates, or where adherence with weekly/monthly oral regimens is a concern. Duration of treatment should be reviewed regularly with your consultant.

Denosumab

UK brand: Prolia

Mechanism: A monoclonal antibody that inhibits RANKL, preventing the formation and activation of osteoclasts. Comparable or superior bone density gains to bisphosphonates in head-to-head trials.

Administration: Subcutaneous injection every 6 months.

Clinical note: Unlike bisphosphonates, denosumab’s effect is reversible on discontinuation — a rapid rebound in bone resorption has been reported after stopping. Sequential antiresorptive therapy should be planned with the consultant before commencing.

Raloxifene

UK brand: Evista

Mechanism: A selective oestrogen receptor modulator (SERM) that mimics oestrogen’s beneficial effects on bone density in post-menopausal women without stimulating breast or uterine tissue.

Administration: Oral daily.

Clinical note: Reduces vertebral fracture risk in post-menopausal women. Less effective for non-vertebral fractures than bisphosphonates.

Hormone Replacement Therapy (HRT)

UK brand: Various preparations (Estradiol, combined preparations)

Mechanism: Oestrogen supplementation maintains and can modestly improve bone density in post-menopausal women by preserving oestrogen’s inhibitory effect on osteoclast activity.

Administration: Transdermal patches, gel, or oral preparations; combined with progesterone for women with an intact uterus.

Clinical note: Benefit for bone health is greatest when HRT is commenced at or near menopause. Individual benefits and risks, including cardiovascular and breast cancer considerations, should be assessed with the consultant.

Anabolic Group

Teriparatide

UK brand: Forsteo

Mechanism: A synthetic fragment of parathyroid hormone (PTH 1–34) that stimulates osteoblast activity, promoting new bone formation. The first licensed anabolic treatment for osteoporosis.

Administration: Daily subcutaneous self-injection for up to 24 months.

Clinical note: Indicated for patients with severe osteoporosis, very low T-scores, multiple vertebral fractures, or inadequate response to antiresorptive therapy. Followed by antiresorptive treatment after the anabolic course to consolidate BMD gains.

Romosozumab

UK brand: Evenity

Mechanism: A monoclonal antibody that inhibits sclerostin, simultaneously stimulating bone formation and inhibiting bone resorption — a dual mechanism unique among osteoporosis therapies.

Administration: Monthly subcutaneous injection for 12 months.

Clinical note: Approved for post-menopausal women at high fracture risk. Produces rapid and large BMD gains in both spine and hip.

A Note on Sequential Therapy

For many patients with osteoporosis, the most effective long-term strategy involves a planned sequence of treatments rather than a single agent. Anabolic therapy is often used first to build new bone, followed by antiresorptive treatment to preserve the gains achieved. The specific sequence — and the duration of each phase — is determined by the individual patient’s clinical profile, bone density trajectory, fracture history, and tolerability.

Treatment holidays, sequential switching, and combination approaches are all part of the modern management toolkit for osteoporosis. Your consultant will discuss the most appropriate treatment strategy for your specific situation at each review appointment.

Exercise is not an optional adjunct to osteoporosis treatment — it is a clinical intervention. The mechanical loading of bone through weight-bearing and resistance exercise provides the stimulus that osteoblasts need to form new bone tissue. But not all exercise is equal, and the type, intensity, and progression of the exercise programme matters significantly.

Resistance training	Progressive loading of targeted muscle groups creates direct mechanical strain on bone at insertion points, stimulating osteoblast activity. Particularly effective for hip and spine density preservation.
Weight-bearing impact	Ground reaction forces from walking, jogging, stair climbing, and jumping transmit loading signals through the skeleton. Variety of direction and speed maximises osteogenic stimulus.
Postural strengthening	Spinal extensor and core strengthening reduce the risk of vertebral fractures and kyphotic posture progression in patients with existing vertebral involvement.
Balance & proprioception	Falls prevention work — targeting balance, ankle stability, and reaction time — directly reduces the incidence of fractures by reducing the incidence of falls.
Pilates	Clinical Pilates develops core control, spinal alignment awareness, and safe movement patterns — particularly relevant for patients with vertebral fractures or existing kyphosis.

At the London Osteoporosis Clinic, therapeutic exercise is delivered by our specialist Strength & Conditioning Coach and clinical exercise team — in clinic, in our exercise classes, or with a personalised home programme designed alongside the consultant’s assessment findings.

All exercise prescriptions are adapted to individual DXA results, fracture history, and physical capacity.

View our exercise classes →

Nutrition plays a crucial role in preventing the development of osteoporosis, but many people aren’t aware that food also aids treatment. It plays such a vital role that drug treatment and other interventions are rendered less effective without adequate nutrition. After all, to form new bone tissue, your body requires certain raw materials to work with. This includes minerals like calcium, magnesium, and phosphorus.

At the London Osteoporosis Clinic, nutritional assessment and supplementation guidance is provided by our registered nutritional therapist as part of the BoneRevive® Programme — personalised to your clinical profile and absorption status, not a generic supplement list.

For more nutritional information, we offer this free educational programme.

Essential Nutrients

Vitamin D: Essential for helping your body absorb the calcium in your food. Doctors can quickly assess a patient’s levels via a simple blood test. Margarine, cereals, and even some dairy products have vitamin D added to them. Some foods naturally contain vitamin D, such as fatty fish and eggs. Multi-vitamin supplements can help improve the body’s vitamin D levels. Ten minutes of sunlight per day is also recommended.
Calcium: Vital for bone health and is also needed for muscle contraction, heartbeat rate and the blood clotting mechanism. Along with consuming the required amount of calcium daily, your body can only use it if your other needs are met. Find out more here.
Protein: Our bodies require a healthy protein intake throughout our lives to sustain our muscle strength, which helps bone density and reduces the risk of falls.
Magnesium: Helps with calcium absorption and metabolism. Studies show that supplementing the diet with magnesium can help prevent bone fractures in people. Furthermore, it’s also essential for muscle contraction and many other functions, all of which contribute to adequate bone health and tissue formation.
Vitamin K2: Plays a recognised role in directing calcium to bone tissue rather than arteries. It is widely used in bone health supplementation alongside Calcium and Vitamin D.

Lifestyle Adjustments

Avoid smoking: Smoking is independently associated with accelerated bone loss through multiple mechanisms — suppression of osteoblast activity, reduced calcium absorption, and accelerated oestrogen metabolism in women. Cessation at any age reduces ongoing skeletal damage, and the benefit of stopping is measurable within a relatively short timeframe.
Avoid excessive alcohol: Chronic alcohol consumption suppresses osteoblast function, increases falls risk through balance impairment, and is associated with reduced Vitamin D and calcium absorption.
Prevent falls: Wear low-heeled shoes with non-slip soles, and check the house for hazards that might cause you to trip or fall. Keep rooms brightly lit, install grab bars inside and outside your shower door, and ensure you can quickly get in and out of your bed. Targeted balance, strength, and posture work reduces falls risk substantially.

Let’s Discuss Your Treatment Pathway

Every treatment pathway at the London Osteoporosis Clinic begins with a comprehensive consultant assessment — because the right treatment for your bone health depends on your clinical profile, not a generic protocol. No GP referral required. Most private health insurance accepted.

Book a Consultant Assessment →